ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers

ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers

Background Immune checkpoint inhibitors (ICIs) therapy targeting programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) shows promising clinical benefits. However, the relatively low response rate highlights the need to develop an alternative strategy to target PD-1/PD-L1 immune check...

Full description

Bibliographic Details
Main Authors: Wei Huang, Qi Wen, Ting Zeng, Di Wu, Li Yuan, Wei Zhu, Zheng-Zheng Yu, Yun-Ya Liu, Ding Xiao, Shan-Shan Lu, Hong Yi, Xue-Ping Feng, Jie-Ya Qiu, Jian-Hua Zhou, Wei Zhuang, Zhi-Qiang Xiao
Format: Article
Language:English
Published: BMJ Publishing Group 2023-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/3/e006345.full

Internet

https://jitc.bmj.com/content/11/3/e006345.full

Similar Items